210 related articles for article (PubMed ID: 14978885)
1. [Systemic pharmacotherapy in breast cancer].
Boér K
Orv Hetil; 2004 Jan; 145(4):187-92. PubMed ID: 14978885
[No Abstract] [Full Text] [Related]
2. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
3. HER2-positive breast cancer: current treatment strategies.
Perez EA; Baweja M
Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
[No Abstract] [Full Text] [Related]
4. Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.
Mayer EL; Burstein HJ
J Clin Oncol; 2008 Mar; 26(8):1198-200. PubMed ID: 18323544
[No Abstract] [Full Text] [Related]
5. HER2 and response to paclitaxel in node-positive breast cancer.
Roukos DH
N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18193530
[No Abstract] [Full Text] [Related]
6. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
Wang LP; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
[No Abstract] [Full Text] [Related]
7. HER2 and response to paclitaxel in node-positive breast cancer.
Ferretti G; Felici A; Cognetti F
N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18184969
[No Abstract] [Full Text] [Related]
8. HER2 and response to paclitaxel in node-positive breast cancer.
Nash I
N Engl J Med; 2008 Jan; 358(2):198; author reply 198-9. PubMed ID: 18193532
[No Abstract] [Full Text] [Related]
9. [Strategies of breast cancer treatment based on determination of biological subtype].
Semiglazov VF
Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
[No Abstract] [Full Text] [Related]
10. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
Jiang ZF; Shao ZM; Xu BH
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
[No Abstract] [Full Text] [Related]
11. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Ahluwalia MS; Daw HA
J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
[No Abstract] [Full Text] [Related]
12. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
13. [New approaches to the treatment of breast cancer].
Semiglazov VF
Vopr Onkol; 2013; 59(3):288-91. PubMed ID: 23909027
[No Abstract] [Full Text] [Related]
14. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Altundag K; Baptista MZ
Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
[No Abstract] [Full Text] [Related]
15. [Neoadjuvant systemic therapy in breast cancer].
Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
[TBL] [Abstract][Full Text] [Related]
16. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
Burstein HJ; Winer EP
J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
[No Abstract] [Full Text] [Related]
17. [Indications and limitations of primary systemic therapy for operable breast cancer].
Yamamoto N; Suzuki M; Tanabe N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():500-6. PubMed ID: 17682201
[No Abstract] [Full Text] [Related]
18. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
Dent R; Clemons M
Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
[No Abstract] [Full Text] [Related]
19. [Breast cancer therapy with combination of endocrine and target drugs].
Korman DB
Vopr Onkol; 2011; 57(1):14-24. PubMed ID: 21598703
[No Abstract] [Full Text] [Related]
20. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
